# Irinotecan-ChemoSeed in Surgically Resectable Glioblastoma

Source: https://onco.cc/trials/nct07356973/  
OnCo record `nct07356973` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of irinotecan-ChemoSeed implementation into the resection cavity after surgical resection of GBM in glioma & glioblastoma, run by CRISM Therapeutics LTD, now recruiting.

## Summary

Irinotecan-ChemoSeed in Surgically Resectable Glioblastoma is a phase 2 interventional study registered as NCT07356973 by CRISM Therapeutics LTD, with 147 participants planned, started 2026-08-20 and due to reach its primary completion in 2029-05. Interventions recorded: irinotecan-ChemoSeed implementation into the resection cavity after surgical resection of GBM.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07356973
- Phase: 2
- Setting: Open-label Phase 2 Safety and Efficacy Trial of Irinotecan-ChemoSeed Administered Directly Into the Resection Margin in Patients With Surgically Resectable Glioblastoma
- Sponsor: CRISM Therapeutics LTD
- Enrolled: 147

## Sources

- ClinicalTrials.gov NCT07356973: https://clinicaltrials.gov/study/NCT07356973

## Connected records

- cancers: [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/)

---
JSON: https://onco.cc/api/v1/entities/nct07356973.json